RxDoctor Payments DataLook up a doctor →

Juan Ramirez Castaneda, MD

Neurology · San Antonio, TXNPI 1275797680

Payments from drug & device makers

$1,143,207in general payments, 2019–2025

Across 850 payments — averaging $1344.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$285K
  • UCB SA$259K
  • Boston Scientific$212K
  • MDD US Operations, LLC$150K
  • Amneal Pharmaceuticals LLC$86K
  • Abbott$59K
  • plus $93K from 25 others

What the payments were for

  • Consulting fees$40,9299%
  • Speaking & faculty fees$336,05274%
  • Travel & lodging$64,32014%
  • Food & beverage$14,1003%
  • Education$1,0230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,143,207 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$321,201
Medicare patients
234
Services billed
27,330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate82$427,353
RytaryCarbidopa/Levodopa168$298,321
Droxidopa14$107,267
InbrijaLevodopa15$77,716
GocovriAmantadine Hcl12$52,352
Carbidopa-LevodopaCarbidopa/Levodopa465$12,553
Rasagiline Mesylate89$9,592
Carbidopa-Levodopa ErCarbidopa/Levodopa169$4,923
AmantadineAmantadine Hcl78$2,498
RivastigmineRivastigmine Tartrate54$2,307
Tetrabenazine14$2,185
Clonazepam87$2,171
Propranolol Hcl ErPropranolol Hcl73$1,947
Propranolol Hcl90$1,360
Primidone62$1,295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$24,556$427,35382 claims
Amneal Pharmaceuticals LLCRytary$85,644$298,321168 claims
Acorda Therapeutics, IncInbrija$49,023$77,71615 claims
MDD US Operations, LLCGocovri$150,364$52,35212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.

Other neurology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →